Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents

Circulation Journal

Volumn 74, Issue 4, 2010, Pages 679-685

  Tsukahara, Kengo ^a   Kimura, Kazuo ^a   Morita, Satoshi ^a   Ebina, Toshiaki ^a   Kosuge, Masami ^a   Hibi, Kiyoshi ^a   Okuda, Jun ^a   Iwahashi, Noriaki ^a   Maejima, Nobuhiko ^a   Nakachi, Tatsuya ^a   Ohtsuka, Fumiyuki ^a   Hashiba, Katsutaka ^a   Tahara, Yoshio ^a   Sugano, Teruyasu ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Bleeding complications; Dual antiplatelet therapy; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DOSE RESPONSE; DRUG ELUTING STENT; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PREDICTION; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE;

AGED; ANGIOPLASTY, BALLOON, LASER-ASSISTED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77950681902     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0601     Document Type: Article

References (37)

1. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
2. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
3. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stinting. J Am Coll Cardiol 2005; 46: 1827-1832.
4. Buonamaci P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
5. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
6. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation 2009; 119: 237-242.
7. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
8. Kushner FG, Hard M, Smith SC Jr, King SB III, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
9. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. The effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
10. Moscucci M, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, et al for the GRACE Investigators. Predictors of major bleeding in acute coronary syndromes: The Global registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823.
11. Kinnaird TD, Stabile E, Minz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935.
12. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49: 1362-1368.
13. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007; 100: 1364-1369.
14. Ndrepapa G, Berger PB, Mehilli J, Seyfarth M, Neumann EJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions. J Am Coll Cardiol 2008; 51: 690-697.
15. Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA. Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009; 73: 1-14.
16. Ozeki Y, Sudo T, Nagamura Y, Ito H, Ogawa T, Kimura Y. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res 2001; 101: 65-72.
17. Sudo T, Ito H, Ozeki Y, Kimura Y. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 2001; 133: 1396-1404.
18. Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, et al. Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007; 50: 1132-1137.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
20. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
21. Chen L, Bracey AW, Radovancevic R, Cooper JR Jr, Collard CD, Vaughn W, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004; 128: 425-431.
22. Cuisset T, Frere C, Quilici J, Uhry S, Alessi MC, Bonnet JL. Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder shifting from antiplatelet resistance to bleeding risk assessment? Int J Cardiol 2010; 138: 212-213.
23. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
24. Serebruany VL, Rao S, Siva M, Donovan JL, Kannan AO, Makarov LM, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: Assessment by different bleeding classifications (abstract). Eur Heart J 2009; 30: 326.
25. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al; for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loadingand maintenance-dose clopi-dogrel in patients with planned percutaneous coronary intervention. The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregationthrombolysis in myocardial infarction 44 trial. Circulation 2007; 116: 2923-2932.
26. Wiviott SD, Braunwald E, MaCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-2015.
27. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. HORIZONS-AMI Trial Investigators: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
28. Antoniucci D. The balance between bleeding and ischemic complications in percutaneous coronary intervention practice. Eur Heart J 2008; 10(Supplement J): J21-J25.
29. Kinnaird T, Anderson R, Hill J, Thomas M. Bleeding during percutaneous intervention: Tailoring the approach to minimize risk. Heart 2009; 95: 15-19.
30. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al for the j-Cypher Registry Investigators. Anti-platelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
31. Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H; on behalf of the J-PMS study group. Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration; One year results from CYPHER stent Japan post-marketing surveillance registry (J-PMS). Circ J 2009; 73: 1038-1044.
32. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent throm-bosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
33. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, et al. Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J 2008; 72: 420-426.
34. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
35. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103(Suppl): 20A-26A.
36. Price MJ. Monitoring platelet function to reduce the risk of ischemic and bleeding complications. Am J Cardiol 2009; 103(Suppl): 35A-39A.
37. Bliden KP, Antonino M, Tantry U, Gurbel P. What is the better predictor of long-term post PCI ischemic events? Pre-treatment vs post-treatment platelet reactivity to ADP. Circulation 2007; 116: II-516.